Xalatan eye drops bottle 0.005% 2.5 ml №3

Packaging

3 bottles of 2.5 ml.

Mechanism of action

Xalatan is an analogue of PgF2alpha, it has an antiglaucomal effect. It reduces intraocular pressure by increasing the outflow of aqueous humor through the choroid of the eyeball, does not have a significant effect on the production of aqueous humor and does not affect the hematophthalmic barrier. May slightly change the size of the pupil. The reduction in intraocular pressure begins 3-4 hours after the administration of the drug, the maximum effect after 8-12 hours, the action continues for at least 24 hours.

Indications and usage

Reducing intraocular pressure in patients:
- with open-angle glaucoma;
- with increased intraocular pressure.

Contraindications

Hypersensitivity to latanoprost, benzalkonium chloride or other components of the drug.

Pregnancy and Breastfeeding

Sufficient experience in the use of the drug during pregnancy and lactation is not. The use of Xalatan during pregnancy and lactation is possible only under the supervision of a physician and only if the expected benefit to the mother exceeds the risk of the development of possible side effects in the fetus or infant.
If necessary, the appointment of Xalatan during lactation should be borne in mind that latanoprost and its metabolites may be excreted in breast milk.

Dosage and administration

The drug is instilled into the conjunctival sac of the affected eye, 1 drop 1 time / day, in the evening. In case of skipping a dose, the next use of the drug is carried out as usual (i.e. the dose is not doubled). More frequent use of the drug leads to a decrease in its effectiveness.
If it is necessary to use other eye drops during Xalatan therapy, they should be used with an interval of at least 5 minutes.

Adverse reactions

Local reactions: more than 10% of patients have eye irritation (burning, itching, foreign body sensation after instillation), as well as darkening, thickening and lengthening of eyelashes; in 1-10% of patients - conjunctival hyperemia, transient point epithelial erosion, blepharitis, increased pigmentation of the iris, eye soreness; less than 1% of patients have eyelid edema.
Darkening of the eyelid skin, edema and erosion of the cornea, iritis, uveitis, macular edema, incl. cystic (mainly in patients with aphakia, pseudo-ophakia, damage to the posterior lens capsule or with risk factors for the development of macular edema), local allergic skin reactions on the eyelids, an increase in the number of eyelashes and a violation of the direction of their growth.
Systemic reactions: less than 1% of patients have a skin rash; there may also be a worsening of the course of bronchial asthma, an acute asthmatic attack, shortness of breath.

With caution it is recommended to use Xalatan in patients with aphakia, pseudo-ophakia, damage to the posterior lens capsule and other risk factors for the development of macular edema.
Xalatan may cause a gradual change in eye color by increasing the amount of brown pigment in the iris. This effect is detected mainly in patients with mixed color of the iris, such as blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in the content of melanin in the stromal melanocytes of the iris. Usually brown pigmentation spreads concentrically around the pupil to the periphery of the iris of the eye, while the entire iris or its parts may acquire a more intense brown color. In patients with evenly colored blue, gray, green or brown eyes, changes in eye color after two years of use were very rare. A change in color is not accompanied by any clinical symptoms or pathological changes. After discontinuation of the drug, no further increase in the amount of brown pigment was observed, however, the color change that has already developed may be irreversible. In the presence of nevi or lentigo on the iris, no changes were noted under the influence of therapy.
Before treatment, patients should be informed about the possibility of changing the color of the eyes.In case of an intense change in eye pigmentation, treatment can be stopped. Treatment of only one eye can lead to permanent heterochromia.
When using contact lenses, remove them before instillation and re-install no earlier than 15-20 minutes after instillation of the drug.
The bottle must be closed after each use. Do not touch the eye with a pipette tip.
Use in pediatrics
There is not enough experience with the use of Xalatan in children. The use of the drug in pediatric practice is possible only under the supervision of a physician, and only in the case when the expected benefit from treatment exceeds the risk of possible side effects.
Influence on ability to drive motor transport and control mechanisms
Patients for whom visual clarity is temporarily lost after applying eye drops, are not recommended to drive a car or work with moving machinery for several minutes after instillation of the drug.

Drug interactions

Xalatan has an additive effect when used in combination with beta-blockers (timolol), adrenergic mimetics (epinephrine), carbonic anhydrase inhibitors (acetazolamide) and, to a lesser extent, with m-cholinomimetic (pilocarpine).
Pharmaceutical Interaction
Xalatan is incompatible with eye drops containing thiomersal (precipitation occurs).

Overdosage

Symptoms: irritation of the mucous membrane of the eyes, conjunctival hyperemia or episclera.
Treatment: conduct symptomatic therapy.

Storage conditions

The drug should be stored in a dark place, out of the reach of children at a temperature of 2 ° to 8 ° C.